KUALA LUMPUR – Malaysia will decide whether to proceed with using the AstraZeneca vaccine for the National Covid-19 Immunisation Programme after getting the European Medicines Agency’s (EMA) findings on the jab.
Coordinating Minister Khairy Jamaluddin said the report by the European Union agency will determine whether there is a causal link between the use of the vaccine and blood clots, or thrombosis.
“We will determine whether to go ahead with it, or we may proceed with caution.”
Khairy said Malaysia still has time to decide, as the AstraZeneca vaccine from the Covax facility will arrive only in May.
The issue of the shot was also discussed at the Covid-19 Vaccine Supply Access Guarantee Special Committee meeting yesterday.
According to an EMA twitter post, a press briefing on its safety committee’s conclusion on the review of AstraZeneca and blood clots is planned for 4pm Central European Time today, or 10 pm Malaysian time. – Bernama, April 7, 2021
.jpeg)
